Event-Driven Stocks

Vivani Medical, Inc.

VANINasdaq

Healthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$0$0————
Operating income−$27.6M−$24.7M−$27.0M−$21.2M−$13.3M−$8.9M
Net income−$26.6M−$23.5M−$25.7M−$13.9M−$12.8M−$8.9M
Total assets$39.4M$41.6M$45.8M$51.1M$5.5M$4.5M
Total liabilities$23.7M$24.0M$25.0M$6.8M$3.0M$5.1M
Equity$15.7M$17.6M$20.8M$44.3M$2.5M$1.9M
EPS (diluted)$-0.43$-0.43$-0.50———
Shares out.59.2M55.0M50.7M39.4M23.3M15.7M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
—
Net margin
—
Return on equity
−169.2%
Return on assets
−67.5%
Return on capital (ROCE)
−84.0%
Liabilities / assets
60.1%
Debt / equity
1.50×
Book value / share
$0.27
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-14.41distress
Accruals / assets
−5.8%clean
Piotroski F-Score
1/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
46
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 1 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 2026392,6262.3+11.9%
Apr 30, 2026350,9461.0-33.8%
Apr 15, 2026529,8593.8-0.4%
Mar 31, 2026532,1311.9+65.0%
Mar 13, 2026322,5751.9+11.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spin-offs from Vivani Medical, Inc. (1)

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (3)